Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

Emilie S. Andersen, A. Lund, J. I. Bagger, C Andreasen, MF Grøndahl, Carolyn F. Deacon, Bolette Hartmann, Jens Juul Holst, Filip Krag Knop, Tina Vilsbøll Lauritsen

2 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?'. Together they form a unique fingerprint.

Medicine & Life Sciences